依普利酮效果怎么样

The new generation of selective aldosterone antagonist (eplerenone) was developed by Pfizer/Pharmacia under the trade name Inspra. It was first launched in the United States in 2002 and is used for the treatment of hypertension, heart failure and myocardial infarction. It has definite efficacy in treating hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by the combined use of multiple antihypertensive drugs, the addition of this product can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, the combination of this product with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve the quality of life and reduce mortality.

Between January 26, 2012 and July 3, 2013, a total of 188 DMD patients were screened, of which 42 DMD patients were included in this clinical trial. 42 people were randomly assigned, of which 20 patients received treatment and 22 patients received placebo treatment. Finally, 20 patients in the eplerenone group and 20 patients in the placebo group completed the 0, 6, and 12-month evaluations. At 12 months, left ventricular circumferential strain decreased less in the eplerenone group than in the placebo group. Cystatin C and serum potassium concentrations were within normal ranges in both groups. One 23-year-old patient in the placebo group died from a fat embolism, and another patient dropped out because of long-standing digestive problems. Other adverse reactions were mild: one patient developed seasonal allergies with a brief headache after taking eplerenone, one experienced flushing after taking placebo, and another experienced significant anxiety after taking placebo.